Review
Immunology
R. Fredi Langendonk, Daniel R. Neill, Joanne L. Fothergill
Summary: P. aeruginosa, a priority one pathogen according to the WHO, is in urgent need of new drugs due to the emergence of multidrug-resistant strains. Antimicrobial stewardship faces challenges during the COVID-19 pandemic, with increased use of antibiotics and sanitizers likely accelerating the development of resistance. Developing anti-resistance adjuvant therapies targeting multiple resistance mechanisms may offer promise in combating multidrug resistant P. aeruginosa and extending the effectiveness of traditional antimicrobials.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Review
Multidisciplinary Sciences
Luke N. Yaeger, Victoria E. Coles, Derek C. K. Chan, Lori L. Burrows
Summary: As the number of effective antibiotics decreases, antibiotic resistance has become a pressing issue, particularly with some Pseudomonas aeruginosa isolates showing resistance to all available antibiotics. Research has identified various mechanisms by which P. aeruginosa evades antibiotics, and there are multiple approaches to overcome resistance, including the use of antimicrobial peptides, rational bacteriophage therapy, and immune-based treatments. Promising avenues for future research include drug combinations, antivirulence therapies, and the development of new antipseudomonal drugs.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
(2021)
Article
Immunology
Morgan A. Alford, Ka-Yee G. Choi, Michael J. Trimble, Hamid Masoudi, Pavneet Kalsi, Daniel Pletzer, Robert E. W. Hancock
Summary: Sinusitis is a common condition characterized by persistent inflammation of the nasal cavity, leading to chronic rhinosinusitis. A model described in this study allows for non-invasive tracking of bacterial infection and screening of host responses. Reactive oxidative species production is associated with disease progression, while host-defense peptides can reduce bacterial burden in this model.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Review
Nanoscience & Nanotechnology
Pranav P. Kalelkar, Milan Riddick, Andres J. Garcia
Summary: This review discusses the use of antibacterial biomaterials and non-antibiotic therapies to improve the ability to combat antibiotic resistance and recurring infections. Utilizing biomaterials allows for targeted delivery of multiple agents while reducing systemic adverse effects, showing great potential for future development.
NATURE REVIEWS MATERIALS
(2022)
Review
Biochemical Research Methods
Enrique J. Montagut, M. Pilar Marco
Summary: Quorum sensing (QS) is a crucial bacterial communication system in the virulence and biofilm formation of pathogens. Recent research on the biological and clinical significance of P. aeruginosa AQs has provided insights for the development of more effective infection treatments.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
(2021)
Article
Multidisciplinary Sciences
Li Li, Zuxian Xu, Ruipin Cao, Jiaxin Li, Chang-Jer Wu, Yinglu Wang, Hu Zhu
Summary: We investigated the influence of hydroxyl groups on the anti-quorum-sensing (anti-QS) and anti-biofilm activity of cyclic dipeptides against Pseudomonas aeruginosa PAO1. The presence of hydroxyl groups improved the inhibition of virulence factors and cytotoxicity, but reduced the ability to inhibit biofilm formation. These cyclic dipeptides interacted with the QS-related protein LasR, and the introduction of hydroxyl groups enhanced their self-assembly ability.
Review
Infectious Diseases
Ahmad Ayman Dabbousi, Fouad Dabboussi, Monzer Hamze, Marwan Osman, Issmat I. Kassem
Summary: This study investigated the epidemiology and antimicrobial susceptibility of multidrug-resistant Pseudomonas aeruginosa in Lebanon. The bacterium was found to be predominant in lesions of patients on mechanical ventilation, burn patients, and those with diabetic foot infections and hematological malignancies. Additionally, carbapenem-resistant P. aeruginosa was detected in animals, with a recent emergence in livestock. However, no studies evaluated the contribution of multidrug-resistant P. aeruginosa in the environment to human infections.
Article
Chemistry, Physical
Jong Min An, Sangrim Kang, Chang Woo Koh, Sungnam Park, Myung Sook Oh, Dokyoung Kim
Summary: A new nano-antibiotic formulation based on sceptrin-Au nano-aggregates (SANA) has been developed to combat drug-resistant bacterial infections. SANA showed superior antibiotic/antibiofilm activity with low toxicity to red blood cells and endothelial cells. The feasibility of SANA as a new nano-antibiotic was demonstrated in CRPA-contaminated medical supplies.
NANOSCALE HORIZONS
(2022)
Article
Multidisciplinary Sciences
Mahere Momenijavid, Himen Salimizand, Aazam Korani, Omid Dianat, Bijan Nouri, Rashid Ramazanzadeh, Amjad Ahmadi, Jino Rostamipour, Mohammad Rastegar Khosravi
Summary: This study evaluated the effects of calcium hydroxide on the morphology and physicochemical properties of Enterococcus faecalis biofilm. It was found that calcium hydroxide could contribute to a denser biofilm structure with more cavities and a granular surface, resulting in increased biomass, thickness, colony size, and volume of the biofilm.
SCIENTIFIC REPORTS
(2022)
Article
Chemistry, Multidisciplinary
Louis M. M. Mouterde, Julien Couvreur, Maxime M. J. Langlait, Fanny Brunois, Florent Allais
Summary: The study identified a potentially new cyclohexanone monooxygenase (CHMO) sequence from the complete genome of the Pseudomonas aeruginosa strain Pa1242, which was confirmed through bioconversion to obtain a key precursor 2H-HBO. The novel sequence exhibited CHMO activity and achieved high productivity and total conversion rates through optimization of culture conditions.
Article
Infectious Diseases
Katie A. Parsels, Keri A. Mastro, Jeffrey M. Steele, Stephen J. Thomas, Wesley D. Kufel
Summary: Cefiderocol is a novel siderophore cephalosporin that has shown activity against clinically relevant MDR Gram-negative bacteria. FDA-approved indications include complicated urinary tract infections and hospital-acquired bacterial pneumonia. Clinical trials have demonstrated non-inferiority to standard treatments, but higher all-cause mortality was observed in certain cases.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Zeling Xu, Yanran Li, Huiluo Cao, Meiru Si, Guangming Zhang, Patrick C. Y. Woo, Aixin Yan
Summary: A transferrable Cascade system was established to enable stable and efficient genome editing in heterologous bacterial hosts, demonstrating greater DNA interference activity and editing capacity compared to traditional Cas9 systems. Additionally, an advanced editing system was developed to target genotypes with poor homologous recombination capacity, clinical isolates lacking sequence information, and cells containing anti-CRISPR elements. Lastly, an 'all-in-one' CRISPRi platform was created for simultaneous transcription modulation in bacterial species.
NUCLEIC ACIDS RESEARCH
(2021)
Article
Infectious Diseases
Lorenz Leitner, Aleksandre Ujmajuridze, Nina Chanishvili, Marina Goderdzishvili, Irina Chkonia, Sophia Rigvava, Archil Chkhotua, Giorgi Changashvili, Shawna McCallin, Marc P. Schneider, Martina D. Liechti, Ulrich Mehnert, Lucas M. Bachmann, Wilbert Sybesma, Thomas M. Kessler
Summary: This study aimed to determine the effectiveness of intravesical bacteriophage therapy in treating UTIs. Findings showed that bacteriophage therapy was non-inferior to standard antibiotic treatment, but not superior to placebo bladder irrigation in terms of efficacy or safety. The safety profile of bacteriophages appears to be favorable, suggesting potential for further large-scale clinical studies on their role in UTI treatment.
LANCET INFECTIOUS DISEASES
(2021)
Article
Biotechnology & Applied Microbiology
Lena Hoffmann, Michael-Frederick Sugue, Thomas Brueser
Summary: A new anthranilate-dependent P-antA promoter system for tunable gene expression in pseudomonads has been established, allowing for adjustable gene expression at lower or higher levels. This system was found to work not only in P. fluorescens but also in strains of P. aeruginosa and P. putida, making it potentially useful for a wide range of physiological and biotechnological applications in pseudomonads.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
(2021)
Article
Agronomy
Gaber Attia Abo-Zaid, Ahmed Salah Abdullah, Nadia Abdel-Mohsen Soliman, Ebaa Ebrahim El-Sharouny, Abdulaziz A. Al-Askar, Yiming Su, Ahmed Abdelkhalek, Soraya Abdel-Fattah Sabry
Summary: The secretion of siderophores by Pseudomonas aeruginosa F2 and P. fluorescens JY3 was evaluated and found to have an inhibitory effect on Fusarium oxysporum and Rhizoctonia solani. Two optimized media were used to produce siderophores as biocontrol agents, and the cell-free supernatants containing siderophores were used to prepare bio-friendly formulations. These formulations showed significant reduction in damping-off caused by F. oxysporum and R. solani, as well as promoting the growth of wheat plants.
Article
Microbiology
Suzanne L. Parker, Frantzeska Frantzeskaki, Steven C. Wallis, Chryssa Diakaki, Helen Giamarellou, Despoina Koulenti, Ilias Karaiskos, Jeffrey Lipman, George Dimopoulos, Jason A. Roberts
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2015)
Article
Microbiology
Ilias Karaiskos, Lena E. Friberg, Konstantinos Pontikis, Konstantinos Ioannidis, Vasiliki Tsagkari, Lamprini Galani, Eirini Kostakou, Fotini Baziaka, Charalambos Paskalis, Antonia Koutsoukou, Helen Giamarellou
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2015)
Article
Critical Care Medicine
Mirjam J. D. Dautzenberg, Ann N. Wekesa, Marek Gniadkowski, Anastasia Antoniadou, Helen Giamarellou, George L. Petrikkos, Anna Skiada, Christian Brun-Buisson, Marc J. M. Bonten, Lennie P. G. Derde
CRITICAL CARE MEDICINE
(2015)
Article
Pharmacology & Pharmacy
Ilias Karaiskos, Maria Souli, Helen Giamarellou
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2015)
Letter
Infectious Diseases
Christina Routsi, Stelios Kokkoris, Evangelia Douka, Foteini Ekonomidou, Ilias Karaiskos, Helen Giamarellou
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2015)
Article
Infectious Diseases
D. J. Hetem, L. P. G. Derde, J. Empel, A. Mroczkowska, M. Orczykowska-Kotyna, A. Kozinska, W. Hryniewicz, H. Goossens, M. J. M. Bonten
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2016)
Article
Infectious Diseases
Maria Souli, Ilias Karaiskos, Lambrini Galani, Sofia Maraki, Efstathia Perivolioti, Athina Argyropoulou, Athina Charissiadou, Levantia Zachariadou, Sofia Tsiplakou, Vassiliki Papaioannou, Helen Tsorlini, Helen Katsifa, Vasiliki Baka, Paraskevi Pantazi, Angeliki Paschali, Anna Kyratsa, Eleftheria Trikka-Graphakos, Panagiota Giannopoulou, Evangelos Vogiatzakis, Helen Moraitou, Helen Papadogeorgaki, Helen Avgerinou, Theofano Panagea, Angeliki Pantazatou, Efthymia Petinaki, Giannoula Stamatopoulou, Marina Toutouza, Ioanna Karatzoglou, Konstantina Kontopoulou, Maria Orfanidou, Irene Karantani, Panteleimon Fytas, Konstantina Tzanetou, Evangelia Platsouka, Polyzo Kazila, Anastasia Chli, Ntina Statiri, Helen Giamarellou
INFECTIOUS DISEASES
(2016)
Article
Infectious Diseases
Ilias Karaiskos, Lena E. Friberg, Lambrini Galani, Konstantinos Ioannidis, Emmanouela Katsouda, Zoe Athanassa, Harris Paskalis, Helen Giamarellou
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2016)
Article
Infectious Diseases
Helen Giamarellou
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2016)
Article
Infectious Diseases
Efthymia Giannitsioti, Sofia Athanasia, Diamantis Plachouras, Stavroula Kanellaki, Fani Bobota, Georgia Tzepetzi, Helen Giamarellou
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2016)
Review
Infectious Diseases
Ilias Karaiskos, Anastasia Antoniadou, Helen Giamarellou
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2017)
Review
Biochemistry & Molecular Biology
Ilias Karaiskos, Irene Galani, Maria Souli, Helen Giamarellou
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2019)
Article
Infectious Diseases
Irene Galani, Ilias Karaiskos, Evdokia Angelidis, Vassiliki Papoutsaki, Lamprini Galani, Maria Souli, Anastasia Antoniadou, Helen Giamarellou
Summary: Three ceftazidime-avibactam-resistant KPC-2-producing Klebsiella pneumoniae strains of ST39 were isolated in Greece, with two strains corresponding to KPC-33 and KPC-57, and the third strain corresponding to KPC-44.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2021)
Review
Infectious Diseases
Irene Galani, Ilias Karaiskos, Helen Giamarellou
Summary: Multi-drug-resistant Klebsiella pneumoniae is a major concern in bacterial resistance, with reports of strains developing resistance to Ceftazidime-Avibactam during treatment. Understanding the mechanisms of resistance can help improve the efficacy of current antimicrobials and guide the design of novel therapeutic agents that can overcome resistance mechanisms.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2021)
Review
Infectious Diseases
Ilias Karaiskos, Irene Galani, Vassiliki Papoutsaki, Lamprini Galani, Helen Giamarellou
Summary: The emergence of carbapenemase resistant Gram-negative bacteria is a major public health concern. The review highlights new treatments for infections caused by carbapenemase producing Klebsiella pneumoniae, with a focus on novel antibiotics and beta-lactamase inhibitors. Approvals and developments of new antimicrobial agents show promising outcomes in combating CPKP infections, with potential for improved efficacy and safety profiles in future therapeutic strategies against multidrug-resistant K. pneumoniae.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2022)
Article
Critical Care Medicine
Dhruv Sarma, Jacob C. Jentzer
CRITICAL CARE CLINICS
(2024)
Article
Critical Care Medicine
Gurleen Kaur, David D. Berg
CRITICAL CARE CLINICS
(2024)
Article
Critical Care Medicine
Leon Zhou, Brandon M. Wiley
CRITICAL CARE CLINICS
(2024)
Article
Critical Care Medicine
Emily K. Zern, Rachel C. Frank, Evin Yucel
CRITICAL CARE CLINICS
(2024)
Article
Critical Care Medicine
Damien Smith, Benjamin B. Kenigsberg
CRITICAL CARE CLINICS
(2024)
Article
Critical Care Medicine
Gozde Demiralp, Robert T. Arrigo, Christopher Cassara, Maryl R. Johnson
CRITICAL CARE CLINICS
(2024)
Article
Critical Care Medicine
Katie P. Truong, James N. Kirkpatrick
Summary: The increasing use of MCS in advanced heart failure patients has led to a greater need for end-of-life management, including MCS device withdrawal and advance care planning. Preparedness planning and palliative care services are important in ensuring a smooth transition to the end of life. Ethical dilemmas can complicate end-of-life care, and withdrawal/deactivation should follow a set protocol that addresses psychosocial/spiritual needs and patient comfort.
CRITICAL CARE CLINICS
(2024)
Article
Critical Care Medicine
Brent Klinkhammer, Taya V. Glotzer
CRITICAL CARE CLINICS
(2024)
Article
Critical Care Medicine
Jacob B. Pierce, Willard N. Applefeld, Balimkiz Senman, Daniel B. Loriaux, Patrick R. Lawler, Jason N. Katz
Summary: Due to the increasing medical complexity of patients, heterogeneity of treatment effects in broad clinical syndromes, and significant competing risks for morbidity and mortality, future clinical trials in the CICU are likely to benefit from innovative approaches to trial design, analysis, and execution, such as incorporating novel trial endpoints, Bayesian analysis strategies, trial networks and clinical registries, adaptive platform trials, and comprehensive research programs. It will be crucial for the authors as a field to articulate priorities for future research and embrace these novel techniques that will ultimately help take better care of patients in the contemporary CICU.
CRITICAL CARE CLINICS
(2024)
